Laura Mauri1, Sammy Elmariah2, Robert W Yeh2, Donald E Cutlip3, P Gabriel Steg4, Stephan Windecker5, Stephen D Wiviott6, David J Cohen7, Joseph M Massaro8, Ralph B D'Agostino9, Eugene Braunwald6, Dean J Kereiakes10. 1. Harvard Clinical Research Institute, Boston, USA Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA Harvard Medical School , Boston, USA lmauri1@partners.org. 2. Harvard Clinical Research Institute, Boston, USA Harvard Medical School , Boston, USA Massachusetts General Hospital, Boston, USA. 3. Harvard Clinical Research Institute, Boston, USA Harvard Medical School , Boston, USA Beth Israel Deaconess Medical Center, Boston, USA. 4. Département Hospitalo-Universitaire Fibrosis, Inflammation, and Remodeling, Assistance Publique - Hôpitaux de Paris, Paris, France National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, UK. 5. Bern University Hospital, Bern, Switzerland. 6. Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA Harvard Medical School , Boston, USA. 7. Saint Luke's Mid America Heart Institute, Kansas City, MO, USA University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. 8. Harvard Clinical Research Institute, Boston, USA Boston University School of Public Health, Boston, USA Université Paris-Diderot, INSERM U-1148, Hôpital Bichat, Paris, France. 9. Harvard Clinical Research Institute, Boston, USA Boston University School of Public Health, Boston, USA. 10. The Christ Hospital Heart and Vascular Center, The Lindner Center for Research and Education, Cincinnati, OH, USA.
Abstract
AIMS: In the dual antiplatelet therapy (DAPT) study, continued thienopyridine beyond 12 months after drug-eluting stent placement was associated with increased mortality compared with placebo. We sought to evaluate factors related to mortality in randomized patients receiving either drug-eluting or bare metal stents in the DAPT study. METHODS AND RESULTS:Patients were enrolled after coronary stenting, giventhienopyridine and aspirin for 12 months, randomly assigned to continued thienopyridine or placebo for an additional 18 months (while taking aspirin), and subsequently treated with aspirin alone for another 3 months. A blinded independent adjudication committee evaluated deaths. Among 11 648 randomized patients, rates of all-cause mortality rates were 1.9 vs. 1.5% (continued thienopyridine vs. placebo, P = 0.07), cardiovascular mortality, 1.0 vs. 1.0% (P = 0.97), and non-cardiovascular mortality, 0.9 vs. 0.5% (P = 0.01) over the randomized period (Months 12-30). Rates of fatal bleeding were 0.2 vs. 0.1% (P = 0.81), and deaths related to any prior bleeding were 0.3 vs. 0.2% (P = 0.36), Months 12-33). Cancer incidence did not differ (2.0 vs. 1.6%, P = 0.12). Cancer-related deaths occurred in 0.6 vs. 0.3% (P = 0.02) and were rarely related to bleeding (0.1 vs. 0, P = 0.25). After excluding those occurring in patients with cancer diagnosed before enrolment, rates were 0.4 vs. 0.3% (P = 0.16). CONCLUSION:Bleeding accounted for a minority of deaths among patients treated with continued thienopyridine. Cancer-related death in association with thienopyridine therapy was mainly not related to bleeding and may be a chance finding. Caution is warranted when considering extended thienopyridine in patients with advanced cancer. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00977938. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIMS: In the dual antiplatelet therapy (DAPT) study, continued thienopyridine beyond 12 months after drug-eluting stent placement was associated with increased mortality compared with placebo. We sought to evaluate factors related to mortality in randomized patients receiving either drug-eluting or bare metal stents in the DAPT study. METHODS AND RESULTS:Patients were enrolled after coronary stenting, given thienopyridine and aspirin for 12 months, randomly assigned to continued thienopyridine or placebo for an additional 18 months (while taking aspirin), and subsequently treated with aspirin alone for another 3 months. A blinded independent adjudication committee evaluated deaths. Among 11 648 randomized patients, rates of all-cause mortality rates were 1.9 vs. 1.5% (continued thienopyridine vs. placebo, P = 0.07), cardiovascular mortality, 1.0 vs. 1.0% (P = 0.97), and non-cardiovascular mortality, 0.9 vs. 0.5% (P = 0.01) over the randomized period (Months 12-30). Rates of fatal bleeding were 0.2 vs. 0.1% (P = 0.81), and deaths related to any prior bleeding were 0.3 vs. 0.2% (P = 0.36), Months 12-33). Cancer incidence did not differ (2.0 vs. 1.6%, P = 0.12). Cancer-related deaths occurred in 0.6 vs. 0.3% (P = 0.02) and were rarely related to bleeding (0.1 vs. 0, P = 0.25). After excluding those occurring in patients with cancer diagnosed before enrolment, rates were 0.4 vs. 0.3% (P = 0.16). CONCLUSION:Bleeding accounted for a minority of deaths among patients treated with continued thienopyridine. Cancer-related death in association with thienopyridine therapy was mainly not related to bleeding and may be a chance finding. Caution is warranted when considering extended thienopyridine in patients with advanced cancer. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00977938. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Donald E Cutlip; Stephan Windecker; Roxana Mehran; Ashley Boam; David J Cohen; Gerrit-Anne van Es; P Gabriel Steg; Marie-angèle Morel; Laura Mauri; Pascal Vranckx; Eugene McFadden; Alexandra Lansky; Martial Hamon; Mitchell W Krucoff; Patrick W Serruys Journal: Circulation Date: 2007-05-01 Impact factor: 29.690
Authors: Gennaro Giustino; Usman Baber; Samantha Sartori; Roxana Mehran; Ioannis Mastoris; Annapoorna S Kini; Samin K Sharma; Stuart J Pocock; George D Dangas Journal: J Am Coll Cardiol Date: 2015-02-11 Impact factor: 24.094
Authors: John W Eikelboom; Shamir R Mehta; Sonia S Anand; Changchun Xie; Keith A A Fox; Salim Yusuf Journal: Circulation Date: 2006-08-14 Impact factor: 29.690
Authors: Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine Journal: N Engl J Med Date: 2015-03-14 Impact factor: 91.245
Authors: Eric A Secemsky; Alexis Matteau; Robert W Yeh; Philippe Gabriel Steg; Edoardo Camenzind; William Wijns; Eugene McFadden; Laura Mauri Journal: Am J Cardiol Date: 2015-03-23 Impact factor: 2.778
Authors: Jacob A Udell; Marc P Bonaca; Jean-Philippe Collet; A Michael Lincoff; Dean J Kereiakes; Francesco Costa; Cheol Whan Lee; Laura Mauri; Marco Valgimigli; Seung-Jung Park; Gilles Montalescot; Marc S Sabatine; Eugene Braunwald; Deepak L Bhatt Journal: Eur Heart J Date: 2015-08-31 Impact factor: 29.983
Authors: Frederick A Spencer; Mauro Moscucci; Christopher B Granger; Joel M Gore; Robert J Goldberg; Philippe Gabriel Steg; Shaun G Goodman; Andrzej Budaj; Gordon FitzGerald; Keith A A Fox Journal: Circulation Date: 2007-11-19 Impact factor: 29.690
Authors: Rafail Angelos Kotronias; Chun Shing Kwok; Chun Wai Wong; Tim Kinnaird; Azfar Zaman; Mamas A Mamas Journal: Drug Saf Date: 2017-03 Impact factor: 5.606
Authors: Mandeep S Sidhu; Karen P Alexander; Zhen Huang; Sean M O'Brien; Bernard R Chaitman; Gregg W Stone; Jonathan D Newman; William E Boden; Aldo P Maggioni; Philippe Gabriel Steg; Thomas B Ferguson; Marcin Demkow; Jesus Peteiro; Gurpreet S Wander; Denis C Phaneuf; Mark A De Belder; Rolf Doerr; Erick Alexanderson-Rosas; Carisi A Polanczyk; Peter A Henriksen; Dwayne S G Conway; Vicente Miro; Tali Sharir; Renato D Lopes; James K Min; Daniel S Berman; Frank W Rockhold; Stephen Balter; David Borrego; Yves D Rosenberg; Sripal Bangalore; Harmony R Reynolds; Judith S Hochman; David J Maron Journal: Am Heart J Date: 2022-02-09 Impact factor: 5.099
Authors: J M Ten Berg; B Zwart; A W J van 't Hof; A Liem; J Waltenberger; R J de Winter; J W Jukema Journal: Neth Heart J Date: 2017-12 Impact factor: 2.380